Home › Funds › BENDER ROBERT & ASSOCIATES › BCRX

BENDER ROBERT & ASSOCIATES position in BCRX

BIOCRYST PHARMACEUTICALS INC · Health Care

BENDER ROBERT & ASSOCIATES reported holding 23,710 shares of BCRX (BIOCRYST PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$198K, representing 0.04% of its reported portfolio and ranking #45 among its reported holdings. BENDER ROBERT & ASSOCIATES has disclosed BCRX holdings in 7 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)23.71K sh
Reported value held$197.50K
Portfolio Weight0.04%
First reportedQ3 2023
Last changeNew
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How BENDER ROBERT & ASSOCIATES's BCRX position evolved

BENDER ROBERT & ASSOCIATES first disclosed a stake in BCRX in Q3 2023 at 56,600 shares (US$401K). Across 7 filings, BENDER ROBERT & ASSOCIATES held the position steady without any share-count change. The most recent filing (Q3 2026) shows 23,710 shares valued at US$198K.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 56.60K $400.73K New
Q4 2023 56.60K $339.03K Hold
Q4 2024 23.71K $178.30K New
Q2 2025 23.71K $212.44K New
Q3 2025 23.71K $179.96K Hold
Q1 2026 23.71K $225.72K New
Q3 2026 23.71K $197.50K New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BCRX and 13F data

BCRX (BIOCRYST PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in BCRX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$158.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$151.0M), TCG Crossover Management, LLC (US$110.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BCRX

All BCRX fund holders →

FAQ

How long has BENDER ROBERT & ASSOCIATES held BCRX?

BENDER ROBERT & ASSOCIATES has disclosed BCRX holdings in 7 of the last 13 reported quarters, going back to Q3 2023.

What is BENDER ROBERT & ASSOCIATES's current position in BCRX?

As of Q3 2026, BENDER ROBERT & ASSOCIATES holds 23.71K shares of BCRX (BIOCRYST PHARMACEUTICALS INC), valued at $197.50K, representing 0.04% of its reported portfolio and ranking #45.

Has BENDER ROBERT & ASSOCIATES been buying or selling BCRX?

In the latest 13F filing (Q3 2026), BENDER ROBERT & ASSOCIATES newly opened its position in BCRX.

Which other funds hold BCRX?

Other major institutional holders of BCRX include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., TCG Crossover Management, LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.